Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Panel Kills Merck's Hope of OTC Status

Looks like the third time won't be the charm for Merck's (NYSE: MRK  ) MEVACOR. Yesterday an FDA advisory panel voted 10-2 that the drug not be given over-the-counter (OTC) status.

Merck has been trying for seven years to get the FDA to move the cholesterol-lowering drug to a more convenient place for customers. Its failed bids in 2000 and in 2005 were essentially because the FDA was worried that customers wouldn't make the right choice about whether they should be taking the drug and caused Johnson & Johnson (NYSE: JNJ  ) to back out of its marketing partnership with Merck.

Merck ran studies to try and show that consumers really are smart enough to know if they should be taking the drug, but the FDA and its advisory panel were still worried about a subset of mock patients who said they would buy the drug even though it wasn't appropriate for them.

The OTC status could have been a boon to Merck and its recently announced marketing partner GlaxoSmithKline (NYSE: GSK  ) . MEVACOR has long since been overtaken by newer statins, including Pfizer's (NYSE: PFE  ) Lipitor, AstraZeneca's (NYSE: AZN  ) Crestor, and Merck's own ZOCOR, but the OTC status could have broadened the market to include patients with milder cholesterol issues who aren't currently on medication. Even though MEVACOR is off-patent, the duo would still get three years of marketing exclusivity before generic competitors could market it OTC.

While the advisory panel vote isn't binding, when combined with the negative FDA summary that FDA reviewers presented to the panel, it seems unlikely that the agency will make the status change. The decision certainly won't give Merck a heart attack; it still has its cholesterol drugs from its partnership with Schering-Plough (NYSE: SGP  ) , as well as a pipeline that contains a few cholesterol drugs.

More Foolishness available OTC:

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 554169, ~/Articles/ArticleHandler.aspx, 11/30/2015 11:25:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 1 hour ago Sponsored by:
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASD 5,108.67 -18.86 -0.37%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/30/2015 4:01 PM
MRK $53.01 Down -0.95 -1.76%
Merck & Co., Inc. CAPS Rating: ****
AZN $34.05 Down +0.00 +0.00%
AstraZeneca plc (A… CAPS Rating: ****
GSK $40.51 Down -0.45 -1.10%
GlaxoSmithKline CAPS Rating: ****
JNJ $101.24 Down -1.13 -1.10%
Johnson & Johnson CAPS Rating: ****
PFE $32.77 Down -0.02 -0.06%
Pfizer CAPS Rating: ****
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****